ALL MEDICAL SPECIALTIES INVITED. FREE REGISTRATION.
CLICK HERE TO REGISTER ONLINE
JAK/TYK2 Inhibition: New Frontiers in the Treatment of Psoriasis
Seemal R. Desai, MD, FAAD
Clinical Assistant Professor
Department of Dermatology
University of Texas Southwestern Medical Center
This activity is provided by the University of Cincinnati.
Paradigm Medical Communications, LLC is the educational partner.
Disclosure of Commercial Support
This activity is supported by an educational grant from Bristol-Myers Squibb.
This initiative has been designed to address the educational needs of dermatology clinicians. It may also be of benefit to rheumatology and primary care clinicians, as well as other healthcare providers (HCPs) involved with or interested in the management of patients with psoriasis.
Statement of Need
Psoriasis is a common autoimmune disorder with associated comorbidities that are more than skin deep. Patients with psoriasis are at increased risk for cardiovascular and metabolic disease, malignancies, and anxiety/depression. This activity will provide clinicians with a solid foundation for understanding the pathophysiology of psoriasis along with other autoimmune diseases, how this pathophysiology informs treatment options, and the most recent clinical trial data for current and emerging agents and management recommendations available to guide therapy selection.
Upon proper completion of this activity, participants should be better able to:
- Identify the JAK/TYK2-STAT–mediated pathways involved in the pathophysiology of psoriasis
- Summarize evidence for the efficacy, safety, and mechanisms of action for new and emerging agents in psoriasis, and the implications for treatment
- Apply current research findings and recommendations to the treatment of psoriasis and comorbidities
- Pathophysiology of Psoriasis
- JAK/TYK2 Inhibitors in Psoriasis Data
- Psoriasis Treatment Guidelines
- New Directions in Psoriasis Therapy: The Role of Emerging JAK/TYK2 Inhibitors in Psoriasis
Physician Accreditation Statement
The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation Statement
The University of Cincinnati designates this virtual live program for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
How to Receive Your CME Credit
- Register here with your professional information and complete the pre-activity survey
- View the online activity in its entirety
- Click here to log-in and complete your post-activity survey and evaluation. You may also click on the Get Credit option on the GlobalMeet platform during the meeting.
A certificate of participation will be available for immediate download. You will also receive an email containing a link to download your certificate.
For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949 or firstname.lastname@example.org.
In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below. Any potential conflicts of interest have been resolved.
April W. Armstrong, MD MPH
Consulting Fees: Abbvie Inc; Bristol-Meyers Squibb Company; Dermavant Sciences Inc; Eli Lilly and Company; Janssen Pharmaceuticals, Inc; LEO Pharma Inc; Modernizing Medicine; Novartis; Ortho Dermatologics; Pfizer Inc; Regeneron Pharmaceuticals, Inc; Sanofi Genzyme; Sun Pharmaceutical Industries Ltd
Grant/Research Support: Abbvie Inc; Bristol-Meyers Squibb Company; Dermavant Sciences, Inc; Dermira;
Eli Lilly and Company; Janssen Pharmaceuticals, Inc; Kyowa Kirin Pharmaceutical Research, Inc; LEO Pharma Inc; Novartis; Regeneron Pharmaceuticals Inc; Sanofi Genzyme; UCB Inc
Seemal R. Desai, MD, FAAD
Consulting Fees: Bristol-Myers Squibb Company; Pfizer Inc
Speakers Bureau: Pfizer Inc
Gary Goldenberg, MD
Consulting Fees: Abbvie Inc; Eli Lilly and Company; Pfizer Inc
Speakers Bureau: Abbvie Inc; Eli Lilly and Company; Pfizer Inc
University of Cincinnati staff members have no financial relationships to disclose.
Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.
Independent peer, resident/fellow, and patient reviewers has no financial relationships to disclose.
Resolution of Conflict of Interest
The University of Cincinnati has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC’s activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality.